NCT04808752View on ClinicalTrials.gov

Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

July 9, 2021

Primary Completion Date

June 15, 2024

Study Completion Date

July 15, 2024

Conditions
Lung Cancer
Interventions
DRUG

Almonertinib

Patients meeting the criteria for inclusion and exclusion were included in the high-dose almonertinib treatment group and received oral almonertinib 165 mg once a day.

Trial Locations (1)

310000

Cancer Hospital Affiliated to University of Chinese Academy of Sciences, Hangzhou

Sponsors
All Listed Sponsors
collaborator

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY

lead

Zhejiang Cancer Hospital

OTHER

NCT04808752 - Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases | Biotech Hunter | Biotech Hunter